<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996436</url>
  </required_header>
  <id_info>
    <org_study_id>IVT_201310 (HSC-MS-13-0586)</org_study_id>
    <nct_id>NCT01996436</nct_id>
  </id_info>
  <brief_title>The Intra-arterial Vasospasm Trial</brief_title>
  <acronym>iVAST</acronym>
  <official_title>The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lenox Hill Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the optimal intra-arterial drug treatment&#xD;
      regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal&#xD;
      subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome at 90 days&#xD;
      post discharge following optimal intra-arterial drug treatment for cerebral vasospasm.&#xD;
&#xD;
      We hypothesize that Intra-arterial (IA) infusion of a combination of multiple vasodilators is&#xD;
      more efficacious than single agent treatment cerebral vasospasm therapy.&#xD;
&#xD;
      All procedures done as a part of this study are standard hospital care procedures done to&#xD;
      treat cerebral vasospasm and all drugs to be used are FDA approved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine the optimal intra-arterial drug treatment&#xD;
      regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal&#xD;
      subarachnoid hemorrhage.&#xD;
&#xD;
      The secondary objective is to evaluate clinical outcome at 90 days post discharge following&#xD;
      optimal intra-arterial drug treatment for cerebral vasospasm.&#xD;
&#xD;
      This study is a prospective multicenter randomized trial. The primary outcome measure is the&#xD;
      Post infusion improvement ratio (PIIR) assessed 10 minutes after completion of the&#xD;
      intra-arterial infusion. PIIR is a measure of arterial lumen diameter pre and post&#xD;
      intra-arterial drug infusion in the presenting vasospasmic blood vessel.&#xD;
&#xD;
      Modified Rankin score (mRS) at 3 months post hospital discharge will be recorded as a&#xD;
      secondary outcome to assess clinical outcome.&#xD;
&#xD;
      The interventions in this study are a part of routine standard of care (SOC) procedures for&#xD;
      cerebral vasospasm treatment. Following surgical or endovascular intervention for aneurysmal&#xD;
      Subarachnoid Hemorrhage (aSAH) if patients develop cerebral vasospasm refractory to maximal&#xD;
      medical management, endovascular treatment by intra-arterial drug infusion of single drug&#xD;
      agent or cocktail drug agents will be initiated.&#xD;
&#xD;
      Study participants will be randomly assigned to one of the three treatment groups where one&#xD;
      single drug agent or cocktail drug agents will be intra-arterially administered. Pre &amp; post&#xD;
      infusion vasospasmic vessel diameters will be compared. The change in diameter will be&#xD;
      quantified based on the mean percentage change. Three months post hospital discharge, study&#xD;
      participants will be followed up in clinic to evaluate clinical outcome.&#xD;
&#xD;
      The study will require 330 patients in total. The patient population will be hospitalized&#xD;
      patients presenting with cerebral vasospasm post aneurysmal subarachnoid hemorrhage.&#xD;
&#xD;
      Subjects will be stratified by randomization into 3 treatment groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post infusion improvement ratio(PIIR)</measure>
    <time_frame>pre pharmacological angioplasty blood vessel diameter - 0 min, post pharmacological angioplasty blood vessel diameter- 10 min after infusion</time_frame>
    <description>Post infusion improvement ratio(PIIR) = (B - A) / A&#xD;
A = pre-infusion blood vessel diameter B = post infusion blood vessel diameter&#xD;
PIIR across all four treatment arms will be compared and tested for statistical significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To grade clinical outcome using Modified Rankin score</measure>
    <time_frame>3 months post discharge from hospital</time_frame>
    <description>Clinical outcome at 3 months post discharge from hospital after treatment will be evaluated using Modified Rankin score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intra-cranial pressure</measure>
    <time_frame>1 day prior to procedure &amp; 1 day after the procedure</time_frame>
    <description>Intra-cranial pressure will be measured 1 day prior to vasospasm treatment and 1 day after vasospasm treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicardipine + Verapamil + Nitroglycerin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Nicardipine</arm_group_label>
    <other_name>Cardene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine + Verapamil + Nitroglycerin</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Nicardipine + Verapamil + Nitroglycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient, age 18-80 years old, with ruptured aneurysm(s) who experience cerebral&#xD;
             vasospasm post operatively within 3-21 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to obtain consent from patient or patients kin&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  less than 18 years of age of more than 80 years of age&#xD;
&#xD;
          -  Hunt Hess Grade 5 SAH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng R Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ketan R Bulsara, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng R Chen, MD</last_name>
    <phone>713-486-8016</phone>
    <email>Peng.R.Chen@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eddie Aguilar, BA</last_name>
    <phone>713-486-7764</phone>
    <email>Eddie.Aguilar@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ledoux, MD</last_name>
      <phone>516-562-3590</phone>
    </contact>
    <contact_backup>
      <last_name>Sarah Nazir</last_name>
      <email>snazir1@northwell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lenox Hill</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Wolfe, MD</last_name>
      <phone>336-716-3842</phone>
      <email>sqwolfe@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Jenkins</last_name>
      <phone>336.716.3842</phone>
      <email>wejenkin@wakehealth.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Schirmer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Chelsea Derr</last_name>
      <email>cmderr1@geisinger.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sheth, MD</last_name>
      <email>Sunil.A.Sheth@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eddie Aguilar, BA</last_name>
      <phone>713-486-7764</phone>
      <email>Eddie.Aguilar@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sunil Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci. 1994 Jan;1(1):19-26.</citation>
    <PMID>18638721</PMID>
  </reference>
  <reference>
    <citation>Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003 May;98(5):978-84. Review. Erratum in: J Neurosurg. 2003 Dec;99(6):1119.</citation>
    <PMID>12744357</PMID>
  </reference>
  <reference>
    <citation>Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke. 1988 Oct;19(10):1300-5.</citation>
    <PMID>3176090</PMID>
  </reference>
  <reference>
    <citation>Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985 Jul-Aug;16(4):562-72. Review.</citation>
    <PMID>3895589</PMID>
  </reference>
  <reference>
    <citation>Keuskamp J, Murali R, Chao KH. High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008 Mar;108(3):458-63. doi: 10.3171/JNS/2008/108/3/0458.</citation>
    <PMID>18312091</PMID>
  </reference>
  <reference>
    <citation>Linfante I, Delgado-Mederos R, Andreone V, Gounis M, Hendricks L, Wakhloo AK. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery. 2008 Dec;63(6):1080-6; discussion 1086-7. doi: 10.1227/01.NEU.0000327698.66596.35.</citation>
    <PMID>19057319</PMID>
  </reference>
  <reference>
    <citation>Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, Rordorf GA. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004 May;25(5):819-26.</citation>
    <PMID>15140728</PMID>
  </reference>
  <reference>
    <citation>Pierot L, Aggour M, Moret J. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care. 2010 Apr;16(2):110-6. doi: 10.1097/MCC.0b013e3283372ef2. Review.</citation>
    <PMID>20098322</PMID>
  </reference>
  <reference>
    <citation>Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008 Mar;39(3):893-8. doi: 10.1161/STROKEAHA.107.492447. Epub 2008 Jan 31.</citation>
    <PMID>18239182</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Peng Roc Chen</investigator_full_name>
    <investigator_title>Professor in Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>cerebral vasospasm</keyword>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>intra arterial drug treatment for cerebral vasospasm</keyword>
  <keyword>nicardipine milrinone nitroglycerin verapamil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

